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Regression coefﬁcientAbstract In this investigation, 3D pharmacophore modeling studies were performed on a diverse
set of 33 a-benzylthio chalcone derivatives that demonstrate anticancer activity by blocking BCR–
ABL phosphorylation in leukemic cells. Pharmacophore modeling is based on the principle of the
alignment of pharmacophoric features which has been carried out on the same set of molecules.
Five point pharmacophores with one negative ionizable group, one hydrophobic group and three
aromatic rings as pharmacophoric features were developed. Pharmacophore hypothesis HNRRR
1501 yielded a statistically signiﬁcant 3D-QSAR model with R2 value 0.9103 and was considered
to be the best pharmacophore hypothesis. The selected pharmacophore model HNRRR 1501
was externally validated by predicting the activity of test set. The correlation coefﬁcient of
0.8856 was observed between experimental and predicted activities of test set. The features of
pharmacophore were expected to be useful for the design of selective BCR–ABL tyrosine kinase
inhibitors.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.1. Introduction
Chronic myelogenous leukemia (CML) is a slow growing
cancer where white blood cells are produced in excess by
bone marrow.1 In Chronic myelogenous leukemia patients,
the reciprocal translocation between the long arms ofchromosomes 9 and 22, results in the Philadelphia (Ph1)
chromosome.2,3 As evident from in vitro and in vivo stud-
ies, it has been established that the tyrosine kinase activity
of the BCR–ABL is sufﬁcient to cause CML,4–7 which
makes BCR–ABL tyrosine kinase inhibitors as the ﬁrst
line therapy for CML.8 BCR–ABL tyrosine kinase inhibi-
tors inhibit the expression of speciﬁc target genes that con-
tribute to the malignant transformation of Philadelphia
positive cells.9
Traditional natural products have cancer preventing
properties.10 In a recent review, Sharma et al. described the
potential of heterocyclic chalcone analogs as potential
anticancer agents.11 The effectiveness of chalcone derivatives
in different cancers is proved by various researchers from time
to time i.e. leukemia, colorectal adenocarcinoma, melanoma,12
cervical carcinoma, breast cancer, lung carcinoma,13 colon
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Figure 1 Basic structures of chalcone series.
104 R. Bajaj et al.cancer,14,15 chronic myelogenous leukemia,16 and prostate
cancer.17 a-benzylthio chalcone was discovered as a new class
of BCR–ABL tyrosine kinase inhibitors that exhibit cytotoxicity
against leukemia (K562) cells.16
3D-QSAR is a quantitative correlation between struc-
ture and experimental activity of the compounds.18 3D-
QSAR model is developed by using three dimensional
conformers of active compounds and score a compound
on the basis of ﬁtting function that evaluate the align-
ment of three dimensional chemical features (hydrogen
donor, hydrogen acceptor, hydrophobic groups, chargeable
group, and aromatic rings) of the model.19 The activity
of new compounds can be quantitatively predicted by
evaluating how well each compound maps onto the phar-
macophore model.20
In the present study, pharmacophore models have been
generated and validated for the prediction of BCR–ABL
tyrosine kinase inhibitory activity of a-benzylthio chalcone
derivatives using the PHASE module of Schrodinger suite.
The alignment obtained from the pharmacophoric points
is used to derive a pharmacophore based 3D-QSAR
model.202. Experimental
2.1. Dataset
A series of 33 a-benzylthio chalcone derivatives having BCR–
ABL kinase inhibitory activity in leukemic K562 cells was used
for the present studies.16 The IC50 values of BCR–ABL kinase
inhibitory activity were converted to pIC50. Dataset was di-
vided randomly into training and test set by considering the
50% of the total molecules in the training set (seventeen mol-
ecules) and 50% in the test set (sixteen molecules). Training set
was used to generate pharmacophore models and the proposed
models were validated by predicting the activity of test set mol-
ecules. The basic structure for chalcone derivatives is depicted
in Fig. 1 and various substituents are enlisted in Table 1.
2.2. Pharmacophore modeling
In the present work, PHASE21 software has been used to gen-
erate pharmacophore models. The structures of all the training
set molecules were drawn using maestro22 and then subjected
Table 1 BCR–ABL kinase inhibitory activity of a-benzylthio chalcones.
Comp. No. Series R1 R2 R3 R4 R5 R6 R7 X Set
1 A COOH H Br H NO2 Cl H CH2S Training
2 A COOH H Br H NO2 Br H CH2S Training
3 A COOH H Br H NO2 F H CH2S Test
4 A COOH H Cl H NO2 F H CH2S Training
5 A COOH H Cl H NO2 Cl H CH2S Test
6 A COOH H Cl H NO2 Br H CH2S Test
7 A COOH H F H NO2 Cl H CH2S Training
8 A COOH H F H NO2 F H CH2S Training
9 A COOH H F H NO2 Br H CH2S Test
10 A F H F H NO2 F H CH2S Training
11 A COOH H F H NO2 Cl H CH2S Test
12 A COOH F F H NO2 F H CH2S Test
13 A COOH Cl Cl H NO2 Cl H CH2S Training
14 A COOH Cl Cl H NO2 F H CH2S Test
15 A COOH Cl Cl H NO2 Br H CH2S Test
16 A COOH Cl Cl H NO2 F H CH2S Training
17 A COOH H CH3 H NO2 F H CH2S Training
18 A COOH H Br H NO2 F H CH2S Test
19 A COOH H H H NO2 F H CH2SO2 Test
20 A COOH H Br H NO2 F H CH2SO2 Test
21 A COOH H Br H NO2 Cl H CH2SO2 Training
22 A COOH H Br H NO2 F H S Test
23 A COOH H Br H OCH3 F H CH2S Training
24 A COOH H Br H Br OH H CH2S Training
25 A COOH H Br H NO2 OH H CH2S Test
26 A COOH H Br F H H NO2 CH2S Training
27 A COOH H Br H F NO2 H CH2S Test
28 A COOH H Br NO2 H F H CH2S Test
29 A COOH H Br F H NO2 H CH2S Training
30 B – – – – – – – – Training
31 C – – – – – – – – Training
32 D – – – – – – – – Test
33 E – – – – – – – – Training
Table 2 Parameters of ﬁve featured pharmacophore hypothesis.
Sr. No. Hypothesis Survival score R2 F Q2 RMSD
1 HNRRR 1501 20.671 0.91 146 0.71 0.4
2 HNRRR 1507 20.604 0.7949 65.9 0.519 0.54
3 HNRRR 2909 20.604 0.7221 44 0.49 0.62
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structures with correct chiralities for each proposed input
structure. All the structures were ionized at neutral pH 7. Con-
formers were generated with the Monte Carlo method by opti-
mized potential for liquid simulations (OPLS-2005) force ﬁeld
with implicit GB/SA distance-dependent dielectric solvent
model at cutoff root mean square deviation (RMSD) of 1
(MacroModel 9.6 2010) with 1000 iterations using water asTable 3 Distances between different sites of model HNRRR 1501.
Site1 Site2 Distance (A˚)
H6 N7 7.073
H6 R8 5.093
H6 R9 4.417
H6 R10 3.655
N7 R8 9.043the solvent. All the conformers were subsequently minimized
using Truncated Newton Conjugate Gradient (TNCG) mini-
mization up to 500 interactions. A conformer set for each mol-
ecule with a maximum energy difference of 30 kcal/mol relative
to the global energy minimum conformers was preserved.21,22
In the next step for the development of pharmacophore
model, a set of pharmacophoric features namely aromatic ring
(R), hydrogen bond acceptor (A) and hydrophobic groups (H)Site1 Site2 Distance (A˚)
N7 R10 3.532
R8 R9 9.422
R8 R10 6.822
R9 R10 5.893
N7 R9 8.903
Table 4 Angles between different sites of model HNRRR 1501.
Site1 Site2 Site3 Angle () Site1 Site2 Site3 Angle ()
R8 H6 R9 164.3 N7 R8 R9 57.6
R8 H6 R10 101.2 N7 R8 R10 20.1
R9 H6 R10 93.3 R9 R8 R10 20.1
N7 H6 R8 94.6 H6 R9 N7 51.7
N7 H6 R9 98.9 H6 R9 R8 8.4
N7 H6 R10 10.0 H6 R9 R10 38.3
H6 N7 R8 34.2 N7 R9 R8 59.1
H6 N7 R9 29.3 N7 R9 R10 14.7
H6 N7 R10 10.4 R8 R9 R10 46.1
R8 N7 R9 63.3 H6 R10 N7 159.6
R8 N7 R10 41.7 H6 R10 R8 47.1
R9 N7 R9 25.0 H6 R10 R9 48.4
H6 R8 N7 51.2 N7 R10 R8 118.2
H6 R8 R9 7.3 N7 R10 R9 140.3
H6 R8 R10 31.7 R8 R10 R9 95.4
Table 5 Experimental and predicted pKi values of training set molecules based on hypothesis HNRRR 1501.
Comp No. Experimental pKi Predicted pKi Fitness score Comp No. Experimental pKi Predicted pKi Fitness score
1 6.154 5.87 1.62 21 4.602 4.88 1.58
2 6.045 5.79 1.59 23 6.221 5.99 1.53
4 6. 1 6.03 1.79 24 6.698 6.72 1.60
7 6.301 5.87 1.61 26 6.522 6.70 1.59
8 6.397 6.60 2.94 29 4.124 4.45 1.59
10 6.221 6.48 2.91 30 5.124 5.24 1.59
13 6.221 6.58 2.92 31 5.301 4.98 1.59
16 6.522 6.62 3.00 33 5.124 4.98 1.68
17 6.397 6.52 2.91
Figure 2 Hypothesis HNRRR 1501 aligned with representative
compound 8. Pharmacophore features are coded: negative ioniz-
able group (N7), hydrophobic (H6), and three aromatic rings (R8,
R9, R10).
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Figure 3 Relationship between experimental and HNRRR 1501
predicted BCR–ABL tyrosine kinase inhibitory activity of test set
(A) and training set (B) molecules.
106 R. Bajaj et al.was used to create pharmacophore sites for all the prepared li-
gands that could effectively map all critical chemical features
of dataset molecules. Minimum and maximum number of sites
for all the features were 3 and 6, respectively. Pharmacophore
matching tolerance was set to 1A˚. Hypotheses were generated
by a systematic variation of number of sites and the number of
matching active compounds. These selected features were used
to build a series of hypotheses by selecting ﬁnd the common
pharmacophore option in PHASE. Common pharmacophoresare identiﬁed using a tree-based partitioning technique that
groups together similar pharmacophores according to their in-
ter site distances. The regression analysis was performed by
constructing a series of models with an increasing number of
Pharmacophore mapping: Prediction of BCR–ABL kinase inhibitory activity of a-benzylthio chalcones 107PLS factors. 3D-QSAR models were generated for the hypoth-
eses using 18 molecules of training set with one to three PLS
factors and a grid spacing of 1 A˚. The model partitions space
into a grid of uniformly sized cubes. Cubes occupied by the
atoms of each class correspond to a ligand, represented by a
set of bit values (0 or 1). These binary-values were used to de-
velop a correlation with biological activity. Further, common
pharmacophore hypotheses were examined using the survival
score to yield the best alignment of the active ligands using
an overall maximum root mean square deviation (RMSD) va-
lue of 1.2 A˚ for distance tolerance. The hypotheses were scored
using default parameters for site, vector, volume, number of
matches, selectivity and energy terms. Survival score secured
by each hypothesis, is the measure of the quality of alignment
for a particular hypothesis.20,23
2.3. Validation of pharmacophore model
Validation is considered to be a conclusive proof to assess the
predictability of a model. Our priority was to develop a phar-
macophore model that can predict the activity of the molecules
accurately, and it should identify active compounds from a
dataset. In the present study, the prediction of the activity of
test set molecules was used as a method to validate the devel-
oped pharmacophore model. All the test set molecules were
processed similar to the training set molecules, and then the
activities of test set molecules were predicted using the devel-
oped pharmacophore model. The correlation between the
experimental and predicted activities of the test set molecules
was then determined.
3. Results and discussion
BCR–ABL tyrosine kinase activity is essential for the trans-
forming function of the protein. A well-known aspect of
BCR–ABL transformation is its ability to activate multiple sig-
naling pathways that lead to proliferation, reduced growth fac-
tor-dependence and apoptosis, and abnormal interaction with
extra-cellular matrix. Previous reports suggest that the sup-
pression of apoptosis constitutes an important mechanism by
which BCR–ABL drives the expansion of myeloid cells.24–26
Ligand-based drug design relies on the knowledge of
known molecules possessing pharmacological activity that
bind to the biological target of interest. These a-benzylthio
chalcone derivatives may be used to derive a pharmacophore
which deﬁnes the minimum necessary structural characteristics
a molecule must possess in order to bind to the target.27 Li-
gand based approaches consider two or three dimensional
shape, chemistry, and pharmacophoric points to assess similar-Table 6 Experimental and predicted pKi of test set molecules based
Comp. No. Experimental pKi Predicted pKi Fitness score
3 6.522 5.62 1.77
5 6.301 5.81 1.62
6 6.301 6.45 2.94
9 6.397 6.50 2.89
11 6.096 5.58 1.81
12 6.301 6.51 2.91
14 6.397 6.60 2.97
15 6.221 6.55 2.91ity. Ligand based QSAR approaches require a number of ac-
tive molecules having a wide range of activities against target
receptor.28
Seventeen molecules forming the training set were used to
develop the pharmacophore models. Selected features (phar-
macophoric) for creating sites were hydrogen bond acceptor
(A), hydrophobic group (H), aromatic ring (R), hydrogen
bond donor (D), and negatively ionizable group (N). Pharma-
cophore models containing three to six features were gener-
ated. Pharmacophore hypotheses with ﬁve features were
selected (Table 2) and subjected to stringent scoring function
analysis.
HNRRR1501 is the best hypothesis in this study character-
ized by the highest survival score, highest F value and the best
regression coefﬁcient (0.9103). The features represented by this
hypothesis are, one hydrophobic group (H), one negative ion-
izable group (N) and three aromatic rings (R). The distances
and angles between different sites of HNRRR 1501 are given
in Table 3 and Table 4, respectively. For each ligand, one
aligned conformer based on the lowest RMSD of feature atom
coordinates from those of the corresponding reference feature
was superimposed on HNRRR 1501. The ﬁtness scores for all
ligands were observed on model HNRRR 1501. The activity of
a compound corresponds with its ﬁtness score i.e. high ﬁtness
score indicates more activity prediction for a compound.20 Be-
sides checking mapping of a feature, ﬁt function also measures
the distance between the features of a molecule with respect to
features of the hypothesis.20 Table 5 shows the ﬁtness score for
all the molecules of training set. Fig. 2 shows Hypothesis
HNRRR 1501 aligned with representative molecule 8
(pIC50 = 6.397) of the training set.
Another validation method to characterize the quality of
HNRRR 1501 is represented by its capacity for correct activity
prediction of training set molecules. The actual and predicted
BCR–ABL tyrosine kinase inhibitory activity of training set
molecules on the pharmacophore hypothesis HNRRR 1501
are shown in Table 5. The predicted BCR–ABL tyrosine ki-
nase inhibitory activity of training set molecules exhibited a
correlation of 0.9103 with a reported BCR–ABL tyrosine ki-
nase inhibitory activity using model HNRRR 1501 (Fig. 3).
In addition to this survival score analysis and prediction of
activity of training set molecules, the validity of the pharmaco-
phore model HNRRR 1501 was further assessed by predicting
test set activity. Like training set molecules, test set molecules
were also built, minimized and used in conformational analy-
sis. Actual and predicted activity values of test set molecules
are given in Table 6. The predicted BCR–ABL tyrosine kinase
inhibitory activity of test set molecules exhibited a correlation
of 0.8856 with an experimental BCR–ABL tyrosine kinase
inhibitory activity using model HNRRR 1501 (Fig. 3). The re-on hypothesis HNRRR1501.
Comp. No. Experimental pKi Predicted pKi Fitness score
18 6.522 6.62 3.00
19 5.4 5.11 2.93
20 5.9 6.00 2.30
22 6.124 6.14 2.53
25 4.69 4.69 1.79
27 4.455 4.70 1.83
28 4.124 4.45 1.78
32 4.698 5.11 1.66
108 R. Bajaj et al.sults of this study revealed that model HNRRR 1501 can be
used for the prediction of BCR–ABL tyrosine kinase inhibi-
tory activity, as for a reliable model, the squared predictive
correlation coefﬁcient should be >0.6.29,30
4. Conclusion
This study shows the generation of a pharmacophore model
HNRRR 1501 for a-benzylthio chalcones acting as BCR–
ABL tyrosine kinase inhibitor. Hypothesis HNRRR 1501
represents the best pharmacophore model for determining
BCR–ABL tyrosine kinase inhibitor activity. HNRRR 1501
consists of one hydrophobic group, one negative ionizable
group and three aromatic ring features. This pharmacophore
model was able to predict the BCR–ABL tyrosine kinase
inhibitory activity and the validation results also provide an
additional conﬁdence in the proposed pharmacophore model.
Results suggested that the proposed HNRRR 1501 model
can be useful to rationally design and identify the new a-ben-
zylthio chalcones as BCR–ABL tyrosine kinase inhibitor in
large 3D database of molecules.
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